NCT00130897Approved For Marketing不适用
A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- Pfizer
- 试验地点
- 1
研究概览
简要总结
The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.
详细描述
Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for such studies are not required to be reported. Protocol A6181037 has been identified as an Expanded Access trial, and has been registered to ClinicalTrials.gov, however Basic Results will not be posted.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •renal cell carcinoma that is not amendable to standard therapy with curative intent
排除标准
- •current treatment in another therapeutic clinical trial
研究者
研究点 (1)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001Solid Tumor Metastatic Cancer Advanced CancerNCT05511350I-Mab Biopharma US Limited
Enrolling By Invitation
不适用
Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening AnemiaAnemiaNCT01881503Englewood Hospital and Medical Center50
Available
不适用
Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSCBone Marrow Failure SyndromeImmunodeficienciesLeukemiaNCT03145545Children's Hospital of Philadelphia
Approved For Marketing
不适用
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma PatientsRelapsed or Refractory Multiple MyelomaNCT05463939Janssen Research & Development, LLC
已完成
4 期
Expanded Access Protocol Thymus TransplantationPoor Thymic FunctionAthymiaImmunoreconstitutionThymus TransplantationLow T Cell NumbersImmunodeficiencyNCT02274662Sumitomo Pharma Switzerland GmbH11